Networking, science communications, public engagement and advocacy for convergence science
The traditional function of universities is to develop and disseminate the body of knowledge. This is done via research and teaching. Research occurs across the spectrum from blue-sky, fundamental pursuits to addressing specific problems. Research findings are disseminated in a variety of ways such as academic publishing, patenting, industry collaborations, students entering the workforce, start-up companies and workshops.
This free event provides a rare opportunity for the research, business, government and investor communities to come together and engage on this pressing national issue.
Our participants bring to the panel a range of perspectives on the research-industry nexus and many of the issues surrounding research engagement and translation. As recognised leaders in their fields they are influential in effecting change in policy and practice:
Ever wondered why some animals have the ability to grow new arms, legs or even repair damaged hearts, but in humans this capability is lost? Can understanding more about how genes function in other species regeneration deliver new insights into human disease? Join us to hear from a panel of leading researchers about how they are using sophisticated science and new disciplines such as bioinformatics to explore the remarkable powers of regeneration. From muscle and heart development and repair in zebrafish to the role of the immune system in limb regeneration in salamander, learn how this research can impact medicine now and in the future.
Peter Currie received his PhD in Drosophila genetics from Syracuse University, New York, USA. He undertook postdoctoral training in zebrafish development at the Imperial Cancer Research Fund (now Cancer Research UK) in London, UK. He has worked as an independent laboratory head at the UK Medical Research Council Human Genetics Unit in Edinburgh, UK and the Victor Chang Cardiac Research Institute in Sydney, Australia where he headed a research programme focused on skeletal muscle development and regeneration.
His work is centred on understanding how the small freshwater zebrafish is able to build and regenerate both skeletal and cardiac muscle. In 2008 he was appointed Deputy Director of the Australian Regenerative Medicine Institute (ARMI) at Monash University in Melbourne, Australia. He is a recipient of a European Molecular Biology Organization Young Investigators Award and a Wellcome Trust International Research Fellowship and currently is a Principal Research Fellow with the National Health and Medical Research Council in Australia.
James Godwin is an independent research fellow in the Rosenthal Group at ARMI and a recipient of the 2008 Newcomb Cleveland Prize for his work on the molecular basis of nerve dependence in salamander regeneration. His last appointment was at University College in London (UCL) as a research fellow in the Laboratory of Jeremy Brockes where he spent 5 years investigating the mechanisms of salamander regeneration. His PhD was obtained at Melbourne University in the Immunology Research Centre based at St Vincent’s Hospital.
This work examined cross species immune mechanisms and focussed on molecules aimed at limiting immune rejection. His current research program looks at the immunological pathways in amphibians (Axolotls) that promote regeneration and limit the scarring response. His research is focused on finding the immunological molecules capable of extending the regenerative capacity in mammals using both molecular and transgenic technologies.
Mirana Ramialison is head of the Systems Developmental Biology Laboratory at ARMI in Melbourne. She is an NHMRC/NHF Career Development Fellow and leads a multi-disciplinary team of bioinformaticians and molecular biologists, to study heart development, evolution and disease. She takes a systems biology approach to uncover the gene regulatory networks that control gene expression during cardiac development, and identify abnormal interactions that cause congenital diseases.
Prior to joining the ARMI in February 2014, Dr Ramialison was an EMBO and HFSP post-doctoral Fellow at the Victor Chang Cardiac Research Institute in Sydney. She received her Engineering degree from the University of Luminy (France) and PhD at the European Molecular Biology Laboratory (Germany).
Presenter: Dr Joel Kramer, Director of Neuropsychology, Memory and Aging Centre, UCSF
The burden and prevalence of cognitive aging is increasing around the world due to population aging. Cognitive aging stands to impact both developed and developing countries. In this presentation, cognitive aging is explored through a convergence or transdisciplinary perspective. The latest convergent innovations in cognitive aging from the UCSF Memory and Aging Center will be explored for diagnosis, treatment and prevention. Innovations in digital health and neuroimaging will be emphasised.
Date: Monday, 29 June
Venue: Auditorium, The Doherty Institute for Infection and Immunity, 792 Elizabeth Street, Melbourne (Corner Grattan Street)
The Network's newest initiative, the Opening the Vault series, was launched last evening at the Victorian Life Sciences Computation Initiative (VLSCI). The VLSCI operates the world's first supercomputer dedicated to life sciences research. Opening the Vault was Dr Amanda Barnard of the CSIRO, who took the audience of over 70 people through her research and how the VLSCI facility was used to create simulations to model nanoparticles for drug delivery. You can follow the conversation on Twitter by visiting #CSNopenigthevault. You can also view images of those who attended last evening's event. A big thank you to the team at VLSCI for allowing us to Open the Vault.
Next Opening the Vault Event:
Centre for Neural Engineering,
University of Melbourne - "Brain-in-a-Dish, Biosensors and Nanoscale Imaging/Fabrication",
6pm - 7pm (registration to open in August)
Dr Harris Eyre, MBBS, Fulbright Scholar
Convergence science is set to revolutionise health and medicine in the 21st century given the interplays occurring between physical science, computer science and life science - think 3D printing, medical robotics, Big Data, nanotechnology and the medical uses of smart phones and smart watches. Convergence science is defined as the merging of distinct technologies, industries, tools, disciplines or devices into a unified whole to create new pathways and opportunities for diagnosis, treatment and prevention. Convergence relies on a new integrated approach to solving problems too complex for any single discipline. There is a need to further strengthen the convergent approaches to medical research, clinical practice and public health. Therefore further integrating convergence science into medical education is key. In this presentation, Dr Eyre provides an overview of convergence science, practical applications of this discipline, and examples of how convergence science can be integrated into Australian medical education. The focus will be on interdisciplinary education with other health related fields (e.g. molecular biology, engineering, computer science, mathematics, public health and entrepreneurship).
Harris Eyre, MBBS, has recently returned from his time as a Fulbright Scholar at UCLA. He is a researcher and psychiatrist-in-training with a passion at the intersection of convergence science and mental health. This means Harris is exploring the value of convergence approaches to research and clinical innovation in mental health. In his academic career, Harris has written 30 peer-reviewed publications and has presented at national and international meetings. He has research and policy experience in medical education, workforce, neuroscience and mental health. Harris graduated from James Cook University Medical School in North Queensland. In 2013, he was awarded the Australian Medical Association of Queensland’s Junior Doctor of the Year Award for excellence in his activities.
Harold White Lecture Theatre
University of Melbourne
757 Swanston Street (Corner Grattan Street)
Diagnosing illness and disease can be an expensive and time consuming endeavour. For the patient it is often a painful and invasive procedure.
Chemists and engineers are the new innovators in disease identification, developing technologies to improve diagnosis – reducing cost, speeding up the turn-around time for results and allowing for diagnosis ‘on the go’. The expert panellists from research and industry will provide an overview of their work on ‘smart bandages’, instant blood glucose monitoring, and painless microneedles. They will answer your questions on how the field of portable diagnostic devices has advanced and what we can expect in the future.
Diagnostics Panel Members
Professor Nicolas Voelcker
Deputy Director, Mawson Institute,
CBNS, University of South Australia
After completing his PhD thesis in polymer surface chemistry at the DWI Leibniz Institute for Interactive Materials under Professor Hartwig Höcker, Nico received postdoctoral fellowships to work in the area of bio-organic chemistry under Professor Reza Ghadiri at the Scripps Research Institute in La Jolla, California. Following an academic position at Flinders University in Australia, Nico was appointed in 2012 as Professor in Chemistry and Materials Science at the Mawson Institute of the University of South Australia, taking on the role of Deputy Director of the Mawson Institute and Program Leader of the Cooperative Research Centre for Cell Therapy Manufacturing in 2013. Since 2014, he is also Node Leader in the Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology.
Nico’s key research interest lies in the fabrication and surface modification of porous materials for applications in biosensors, biochips, biomaterials and drug delivery. A core research activity in his laboratory is the study of porous silicon based nanostructures and their surface chemistry. Using advanced surface analytical spectroscopy and microscopy techniques, his research has also contributed to the understanding of the fundamental principles of interfacial interactions of proteins, nucleic acids and whole cells on solid surfaces. Using this fundamental understanding, he is also developing new nanostructured materials for biosensors, biochips, biomaterials and drug delivery.
He has authored over 220 peer-reviewed journal articles with over 3500 citations, h-index 32. He has received fellowships from the German Research Foundation (DFG), the CSIRO, the Alexander von Humboldt Foundation and is a recipient of the Tall Poppy Science Award.
Dr Alastair Hodges
Chief Scientist, Universal Biosensors
Dr Alastair Hodges has been working in the field of electrochemical sensors since 1994. He has a BSc (Hons) in chemistry, physics and mathematics and gained a PhD in electrochemistry from The University of Melbourne in 1987.
Alastair worked as a research scientist in the Defence Science and Technology Organisation and the CSIRO in the fields of electrochemistry and membrane transport processes until 1995, when he joined Memtec Limited to work on sensor technologies.
From 1999 to 2001 Alastair led a team that worked in the US on the development of glucose sensor technology. Alastair was a founder of Universal Biosensors Pty Ltd in 2002 as their Chief Scientist. He has been instrumental in inventing and developing the electrochemical sensor technology upon which Universal Biosensors is based.
Alastair has published thirteen papers in refereed journals and is an inventor on more than 50 issued and pending patent families.
Dr Simon Corrie CBNS,
The University of Queensland
Dr Simon Corrie is a recipient of the Australian Research Council’s prestigious Discovery Early Career Researcher Award (2013-2016). He has developed several molecular technologies with applications in diagnostics, publishing the work in Royal Society of Chemistry and American Chemical Society journals and presenting it at international conferences.
After completing his chemical engineering degree and PhD in physical chemistry, Dr Corrie worked in Professor Nancy Kiviat’s HPV Research Laboratory at the University of Washington in Seattle, developing clinically-relevant molecular diagnostic assays. Dr Corrie returned to Queensland on a Smart Futures Fellowship to join Professor Mark Kendall’s research group at the Australian Institute for Bioengineering and Nanotechnology (AIBN), developing a novel diagnostic technology based on Micropatches that capture circulating biomarkers from the skin microvasculature.
MC for Panel Discussion
Dr Simon Tucker,
Former VP Research,
Simon P. Tucker, Ph.D was Vice President, Research of Biota Pharmaceuticals, Inc for 18 years. Biota was the originator of the first drug in the neuraminidase class of influenza antivirals and has a particularly strong background in respiratory antivirals. Among the many discoveries made by the Biota R&D team are included the most potent influenza antiviral described to date, a novel antiviral for picornavirus that is currently in Phase II, several novel series of RSV antivirals and two new classes of antibiotics.
Prior to Biota Simon held the position of Senior Lecturer and Head of The Gene Therapy Laboratory at the University of Glasgow, UK and before then Senior Research Investigator, Infectious Disease Research, G. D. Searle Research and Development, St Louis, MO, USA.
Simon received his BSc (Hons) degree in biochemistry from the University of Sussex, UK. He completed his PhD in 1988 through the University of Reading, UK while studying avian influenza in the Director's Group, Institute for Animal Health, Pirbright, UK. His postdoctoral work was undertaken at the University of Alabama, Birmingham, AL, USA where he also served as a Senior Research Fellow before joining Searle.
His background is in virology with a particular interest in the discovery and development of new therapies. He has led multidisciplinary discovery teams and has been associated with numerous potential drugs that reached clinical trials, together with some that achieved registration and marketing. He has also overseen the development and launch of one the first influenza point-of-care diagnostic tests for influenza A and B.
Thursday, 27 August 2015
5.00 PM – 6.00 PM Serving of refreshments
6.00 pm – 7.15pm Presentations and panel discussion.
Level 2, Building 263
The University of Melbourne
234 Queensberry Street
3-D Brain-in-a-Dish, Autism and Biosensors
The Centre for Neural Engineering (CfNE) is an interdisciplinary centre that has been established at the University of Melbourne to undertake research in neuroscience and neural diseases. The Centre is supported by the Faculties of Engineering, Science and Medicine, Dentistry and Health Sciences. The CfNE is tackling some of the great challenges in the neurosciences and increasing our understanding of neuronal and brain function. Bringing together disparate disciplines for new approaches to old problems, the research activities of the Centre for Neural Engineering are focused on engineering solutions for childhood brain and mind disorders. Work is clustered around the Disorder Flagships – Autism Spectrum Disorder (ASD) and Epilepsy – and the Technology Flagships – Neural Modelling and Sensing.
The Opening the Vault @ The CfNE will include:
And there will be a few other surprises as well!
There will be a strict limit of 50 places only and a waitlist will be created if necessary. Tickets will need to be presented at the door. If there is overwhelming demand, the Network will raise with the Centre the possibility of holding another tour at a later date for those who miss out on this occasion. Refreshments will be served.
The Real Silent Witness
Forensic medicine, a voice from the grave
at the Doherty Institute
Demystifying Attention Deficit Hyperactivity Disorder (ADHD)
at the Doherty Institute
ADHD is undoubtedly the most controversial disorder of our time. Controversy arises because of the use of psychostimulant medications in its treatment and by a perception that diagnosis rates are escalating exponentially.
Separating fact from fiction is critically important so that the many thousands of individuals affected by ADHD in Australia can gain access to timely diagnosis and treatment and to educational and occupational opportunities.
In this lecture, Professor Luis Rohde, a world-leading expert on ADHD and President of the World Federation of ADHD, will provide a state-of- the-art perspective on ADHD; its diagnosis, epidemiology, biology and treatment.
Luis A Rohde, MD, PHD
Luis A Rohde, MD, PhD is Professor of Child and Adolescent Psychiatry in the Department of Psychiatry at the Federal University of Rio Grande do Sul, Brazil, Director of the Program for Attention-Deficit/Hyperactivity Disorder at the Hospital de Clinicas de Porto Alegre, and Vice-Coordinator of the National Institute of Developmental Psychiatry for Children and Adolescent, Brazil.
He is currently Associate Editor of the Attention Deficit and Hyperactivity Disorder, International Editor of the J Am Acad Child and Adolescent Psychiatry and former Co-Editor of the European Child and Adolescent Psychiatry.
He is President of the World Federation of ADHD, and was former Vice-President of the International Association of Child and Adolescent Psychiatry and Allied Professions. He also was a member of the American Psychiatric Association working group for defining ADHD diagnosis in the DSM-5.
Dr. Rohde’s research interests include ADHD epidemiology, genetics, pharmacogenetics, neuroimaging, and the effects of pharmacological and psychosocial treatments for ADHD. He has published extensively in peer review international and national journals (more than 280 papers), and has been an author or co-author in over 50 book chapters and editorials. He is editor or organizer of 8 books addressing child and adolescent mental health published in Brazil, UK, Germany and the US.
This event is proudly sponsored by the Melbourne Convention Bureau.
Monday 31 July 2017
6.00 pm – 7.00 pm. Refreshments served from 5.15 pm.
The Auditorium, Peter Doherty Institute for Infection and Immunity
792 Elizabeth Street, Melbourne 3000
Opening the Vault Series - BioFab3D@ACMD
at St Vincent's Hospital Melbourne
Australia's first hospital-based biofabrication, robotics and biomedical engineering research centre. Here, researchers, clinicians, engineers and industry partners are working to build biological structures such as cartilage, muscle, bone, nerves and organs: almost anything that requires repair through disease and physical trauma. Our work is highly geared towards clinical translation and commercialisation.
On this tour, you will get a behind the scenes look at some of the most exciting biomedical research programs in Australia, including the development of a Biopen device for handheld surgical bioprinting (twice listed on the Timeline of Key Australian Medical Technologies), and the development of a robotic hand controlled by the patient's thoughts.
The development of the Biopen allowed surgical printing of adipose stem cells at a chondral wound site
ACMD: Aikenhead Centre for Medical Discovery - Living better for longer
With a focus on biomedical engineering, the Aikenhead Centre for Medical Discovery – a research and academic medical centre – will bring together clinicians, engineers, scientists and students like never before.
The Centre will help achieve three major health outcomes for Australians:
Biomedical engineering innovations will be the Centre’s focus including:
The Aikenhead Centre for Medical Discovery will develop Australia’s future health and research workforce, providing an education experience beyond the text book. Together the partners will generate transformative solutions to health care problems that will improve treatment options, reduce the cost of health care and allow Australians to Live Better for Longer.
Date: Wednesday, 9 August
Time: 3.45 pm – 5.00 pm
Address: Level 1 Clinical Sciences Building (Cnr Princes St & Regent St)
Spaces are limited please book early.
Buffeted by Global Headwinds: Challenges Facing Biomedical Research
Melbourne Exhibition Centre
Australia’s biomedical research community is the envy of many countries. But we cannot be complacent. Biomedical research in Australia faces a number of challenges. Real funding for research has been falling over time. And a cascade of issues confront the community today. These include, but are not limited to, problems with gender equity, career uncertainty for younger researchers, research translation and reproducibility. Some of our best and brightest see no option but to leave the sector the incentives for those at school to take up the challenge are diminishing, and public trust in the process of translating research into clinical practice is at risk.
A number of the structural and political challenges facing Australian biomedical researchers are local in nature, but many are also shared with our colleagues around the world. Failure to confront these challenges will slow the rate of progress on advances in diagnostics, treatments and therapeutics.
Neglected diseases will probably be starved further of research funding. For millions, the possibility of relief from pain and suffering will recede. As part of National Science Week, the Convergence Science Network is pleased to bring together a distinguished panel for a public conversation about the state of biomedical research in Australia. This is an opportunity to understand the headwinds biomedical research faces and to have a say about how we might respond, to ensure we remain a nation that not only enjoys the benefits of cutting edge health care but contributes to a world where good health is not only the preserve of wealthy nations.
The panel will examine a number of questions including:
Joining us on the panel are:
Who should attend?
This event will be of interest to:
We are grateful for the support of the Club Melbourne Ambassador Program as the venue sponsor.
More about the panelists:
SIR GUSTAV NOSSAL, AC, CBE, FAA, FRS
University of Melbourne
GUSTAV NOSSAL was born in Bad Ischl, Austria, in 1931, and came to Australia with his family in 1939. He studied Medicine at The University of Sydney and, after two years' residency at Royal Prince Alfred Hospital, moved to Melbourne to work at The Walter and Eliza Hall Institute of Medical Research, where he has spent most of his research career in immunology. He has written seven books and over 530 scientific articles in this and related fields. Nossal has served as President of the Australian Academy of Science, President of the International Union of Immunological Societies, Chairman of the Victorian Health Promotion Foundation, Chairman of the committee overseeing the Global Programme for Vaccines and Immunization of the World Health Organization, Chairman of the Strategic Advisory Council of the Bill and Melinda Gates Foundation’s Children’s Vaccine Program and Deputy Chairman of the Council for Aboriginal Reconciliation. He was knighted in 1977, made a Companion of the Order of Australia in 1989 and has received numerous honours from 16 countries. In 2000 he was appointed Australian of the Year. He is currently Professor Emeritus, Department of Pathology, The University of Melbourne and a Principal of Foursight Associates Pty Ltd.
Professor Anne Kelso AO
Professor Anne Kelso AO is the Chief Executive Officer of the National Health and Medical Research Council (NHMRC). Before joining NHMRC in April 2015, Professor Kelso spent many years as a biomedical researcher in immunology alongside other roles, most recently as Director of the WHO Collaborating Centre for Reference and Research on Influenza at the Doherty Institute in Melbourne. She is a member of several Government and international committees, including the Australian Medical Research Advisory Board (advising the Minister for Health on the strategy and priorities for the Medical Research Future Fund), the Board of the Global Alliance for Chronic Diseases (chair-elect) and the Human Frontier Science Program Organization.
Professor John Carroll
Monash Biomedical Discovery Institute
Professor John Carroll, Director, Monash Biomedicine Discovery Institute, Professor of Reproductive Biology, Monash University. Professor Carroll's research focus is on the cell biology of the mammalian oocyte with a view to understanding its role in establishing a healthy pregnancy. His current work is directed toward understanding why eggs become less fertile as maternal age increases.
John has spent most of his academic career at University College London (UCL) where he was Head of Department of Physiology before being appointed Associate Dean and Director of the UCL Division of Biosciences.
Professor Carroll joined Monash University in September 2012 where he is Director of the Monash Biomedicine Discovery Institute and Dean of Biomedical and Psychological Sciences. As Director of the Monash BDI, John is a strong advocate for the essential role of fundamental discovery research in the development of the next generation of medicines and therapeutics and in partnering early with industry to ensure the rapid translation and commercialisation of discoveries. John also chairs the Athena SWAN gender equity team at Monash University.
Prof. Darren Kelly,
Darren is the Company’s CEO and Managing Director bringing over 25 years of management and research expertise in the life sciences and biotech sector. Concurrent to his role with OccuRx, Darren is the Associate Dean (Innovation and Commercialisation, MDHS) at The University of Melbourne, and Director Biomedical Research in the Department of Medicine, St Vincent’s Hospital Melbourne, where his research expertise lies in progressing pre-clinical novel interventions and developing experimental models of cardiovascular disease. He has published over 200 manuscripts in the field of translational research and novel interventions many of which have had a direct impact on human disease. In 2009, Darren was a recipient of the prestigious TJ Neale award for outstanding contribution to nephrology. In 2015 Darren joined the Medical Research Commercialisation Fund as Venture Partner.
Darren has proven history in translational research. He was previously Founder, CEO and Director of Fibrotech Therapeutics, a company that developed orally active anti-fibrotic inhibitors to treat underlying pathological fibrosis in kidney and heart failure, which was ultimately acquired by Shire Plc for a record 75 million USD upfront including milestone payments up to 600 million USD.
Darren has a PhD in Translational Medicine from the University of Melbourne. He is a current member of the Australian Institute of Company Directors, AusBiotech, BioMelbourne Network and a Fellow of the American Society of Nephrology.
Dr Sarah Meachem
Hudson Institute of Medical Research
Dr Sarah Meachem is an academic researcher and a health and medical research advocate. She completed her PhD at Monash University in 1999 where she studied hormonal control of testis function, at the Hudson Institute of Medical Research and the author of more than 80 publications. She has engaged in numerous leadership and advocacy roles in the broader Health sector in Australia. Sarah is a Director of the Australian Institute of Policy and Science, a Manager for the co-badged PhD International Research Training Program between Germany and Australia (Monash & Giessen Universities) and was a Director and Past President twice of the peak advocacy for health and medical research, The Australian Society for Medical Research, the associate Director of the Children Cancer Institute Australia (NSW), and a Senior Leader at the National Health and Medical Research Council Australia (ACT). She was the fortunate recipient of the Victorian Tall Poppy Awards for research and communication excellence (2007) and ambassador of the program (Australian Institute of Policy and Science) and was awarded the Australian Leadership award for her vision for the nation’s health sector in 2011. She has 5 years formal communication training in 'leadership, power and performance' and is dedicated to building a fully integrated health care system and a sustainable career structure for the health and medical research workforce.
Dr Rachel Nowak
University of Melbourne
Dr Nowak is recently appointed as Associate Director, Strategic Communications in the Research, Innovation and Commercialisation portfolio at the University of Melbourne.
Previously, Rachel was founder-director of The Brain Dialogue, a prototype engagement program fostering two-way dialogue between the public and researchers about brain research and where it should take us. The Brain Dialogue is an initiative of the Australian Research Council Centre of Excellence for Integrative Brain Function,
Rachel was also principle at Rachel Nowak and Associates, a consultancy that developed new and existing enterprises to share scientific knowledge for innovation, Responsible Research and Innovation (RRI), improving public health and enriching lives, and to link industry and academia. She has a PhD and two post-docs in circadian physiology, and an MA from the Writing Seminars at Johns Hopkins University in Baltimore.
Rachel has worked for several US science and biotech publications, including Science, as senior writer covering biomedicine. She has taught science writing at Johns Hopkins University, and worked at New Scientist, firstly as Washington Bureau Chief, and then as Australasian Editor.
She is a member of the Gene Technology Ethics and Community Consultative Committee of the Office of the Gene Technology Regulator, Department of Health; a non-Executive Director of COSMOS Media Pty Ltd; and a member of the Advisory Board, ARC Centre of Excellence for All-Sky Astrophysics.
This is a free event but registration is essential.
Monday, 14 August 2017
6.00 pm – 7.30 pm.
Clarendon Auditorium, Level 2, Melbourne Exhibition Centre,
2 Clarendon Street, South Wharf (Opposite Crown Casino)
About the Convergence Forum
The Convergence Science Network will announce a series of events in early 2015. Our program will include presentations from science thought leaders and practitioners, events where we explore topical issues in more depth and we¹ll be presenting some of our brightest scientists who will share their exciting work in convergence science.
Convergence Science Symposium
The Convergence Science Network is an initiative that promotes an understanding of convergence science to the community, why it is important and how it is helping researchers and businesses realise their visions in delivering improved health and well-being.
Graeme Clark Oration
Join our community
The Graeme Clark Oration is delivered by global leaders in science in honour of Prof. Graeme Clark’s pioneering work in developing the bionic ear in Melbourne in the 1970’s. It is recognised as Australia’s most prestigious free public science event and is attended by secondary school students.
The Convergence Science Network is excited about its networking activities and is inviting organisations to join this unique science communication and engagement initiative.
Contact us to find out the exclusive benefits available to Network sponsors. We also offer an Individual Membership package of benefits.
We Engage with the community to share developments in convergence science and how these advances impact medicine and health care.
We Inspire the research community, start-ups, existing businesses, government agencies and schools to take advantage of the opportunities offered by convergence science.
We Create the environment and opportunities for new ideas, knowledge and resources across different science disciplines to come together to improve health.